Latest Lexicon Pharmaceuticals (LXRX) Headlines
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Fourth Quarter And Full Year Financial Results
PR Newswire - Fri Feb 28, 6:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2013.
Lexicon to Report Fourth Quarter and Year End 2013 Financial Results on February 28, 2014
PR Newswire - Thu Feb 20, 6:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its fourth quarter and year end 2013 financial results on Friday, February 28, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2013 at 11:00 a.m. Eastern Time on February 28, 2014.
Lexicon Pharmaceuticals Up 11.8%, Shares Break Through Resistance (LXRX)
Comtex SmarTrend(R) - Fri Feb 07, 11:42AM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's best performing low-priced stocks, up 11.8% to $1.89 on 1.2x average daily volume. Lexicon Pharmaceuticals has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (11.8% to the Dow's 0.6%) and outperformed the S&P 500 (11.8% to the S&P's 0.8%) during today's trading.
Lexicon To Present At The BIO CEO And Investor Conference
PR Newswire - Mon Feb 03, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the BIO CEO & Investor Conference on Monday, February 10, at 10:30 AM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 30, 12:30PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 15, 8:31AM CST
An eventful week for the biotech sector with several outperformers like Intercept, Epizyme, Sangamo and Pharmacyclics.
Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart
Eric Volkman, The Motley Fool - Motley Fool - Mon Jan 13, 3:34PM CST
Lexicon Pharmaceuticals is narrowing its business focus in an effort that will lead to a substantial reduction in head count, and its CEO will also be departing. The company announced that it will concentrate its resources on late-stage drug...
Global Mice Model Market Analysis, 2018: Type, Technology, Disease, Service & Care Products Breakdown
M2 - Fri Jan 10, 8:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgjm94/mice_model_market) has announced the addition of the "Global Mice Model Market Analysis, 2018" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The biggest factor that is likely to drive the growth of this market is the ongoing innovations in the development of mice models. In addition, another factor that is likely to drive the growth of the market is the continuous research that is undertaken to develop treatments for fatal diseases such as cancer and HIV/AIDS. Furthermore, research institutes and government bodies have extended their help in the form of investments, funds, and grants, which have stimulated research activities to develop mice models. In addition, the demand for personalized medicines is expected to boost the use of humanized mice models. A number of factors such as advancements in the biotechnology and biopharmaceutical industries as well as the increase in the number of R&D activities in pharmaceutical industries are propelling the growth of the mice model market. However, stringent regulations and laws for ethical use of animals in research are hindering the growth of this market. In addition, the market is facing a threat from advances in zebrafish models and rat models, which are leading to their increased use in research activities. North America is the largest market for mice models, followed by Europe and Asia. Furthermore, the Asian and North American markets for mice models are expected to witness a healthy growth over the next five years. Scope of the Report Type - Inbred Mice - Outbred Mice - Conditioned/Surgically Modified Mice - Hybrid/Congenic Mice - Knockout Mice - Spontaneous Mutant Mice Technology - Microinjection - Embryonic Stem Cell Injection - Virus/Vector Mediated Gene Transfer - Nuclear transfer Technology - Genetically Modified Sperm - Others Disease - Oncology - Immunology & Inflammation - Central Nervous System - Cardiovascular - Diabetes - Metabolism & Regulation - Others Service - Breeding - Cryopreservation - Quarantine - Rederivation - Genetic Testing - Model In-licensing - Other Services (Surgical and Line Rescue) Mice Care Products - Bedding - Feed - Cages - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/dg...del_market
Lexicon To Present At The J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 08, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the J. P. Morgan Healthcare Conference on Wednesday, January 15, at 9:30 AM PST in San Francisco. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.
Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)
Brian Orelli, The Motley Fool - Motley Fool - Tue Jan 07, 5:30PM CST
One failed trial followed by a positive one equals an 11% increase in stock price. Technically Neurocrine Biosciences was up 90% today, but it dropped so much after the first trial, the biotech is only sitting on a relatively modest gain from...
The Billion-Dollar Biotech Club: Speculation Trumped Risk
at The Street - Mon Dec 30, 8:19AM CST
The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
UBM plc Begins Trading on OTCQX®
PR Newswire - Wed Dec 18, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that UBM plc (OTCQX: UBMPY; LSE: UBM), a global business-to-business events-led marketing services and communications business, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX®, the best marketplace with qualified companies.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 17, 4:05PM CST
Just as we examine companies each week that may be rising past their fair value , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
A Fool’s Look Back at Lexicon, Peregrine, and Jazz
George Budwell, The Motley Fool - Motley Fool - Fri Dec 13, 10:02AM CST
The biotech industry has seen a growing number of specialty companies pop up in the last decade, aiming to develop novel platforms that they can then apply across a number of serious diseases that lack effective treatments. But since so many new...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 07, 7:45AM CST
The past couple of weeks in college football have demonstrated how quickly big mistakes can turn around a game. While the college football season is winding down, we can see the same principle practically every week in the world of health-care...
Setback for Lexicon Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 2:35PM CST
Shares of Lexicon Pharmaceuticals, Inc. (LXRX) were down 6.5% in the last two days after the company reported disappointing results from a phase II study.
Investors look to Lighten Up on Shares of Lexicon Pharmaceuticals, Shares Down 5.1% (LXRX)
Comtex SmarTrend(R) - Thu Dec 05, 12:47PM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 5.1% to $2.06 on 1.5x average daily volume. Lexicon Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 800,000 shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.2%) and underperformed the S&P 500 (-5.1% to the S&P's -0.3%) during today's trading.
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Fourth Quarter And Full Year Financial Results
PR Newswire - Fri Feb 28, 6:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2013.
Lexicon to Report Fourth Quarter and Year End 2013 Financial Results on February 28, 2014
PR Newswire - Thu Feb 20, 6:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its fourth quarter and year end 2013 financial results on Friday, February 28, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2013 at 11:00 a.m. Eastern Time on February 28, 2014.
Lexicon Pharmaceuticals Up 11.8%, Shares Break Through Resistance (LXRX)
Comtex SmarTrend(R) - Fri Feb 07, 11:42AM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's best performing low-priced stocks, up 11.8% to $1.89 on 1.2x average daily volume. Lexicon Pharmaceuticals has traded 1.4 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (11.8% to the Dow's 0.6%) and outperformed the S&P 500 (11.8% to the S&P's 0.8%) during today's trading.
Lexicon To Present At The BIO CEO And Investor Conference
PR Newswire - Mon Feb 03, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the BIO CEO & Investor Conference on Monday, February 10, at 10:30 AM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 30, 12:30PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jan 15, 8:31AM CST
An eventful week for the biotech sector with several outperformers like Intercept, Epizyme, Sangamo and Pharmacyclics.
Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart
Eric Volkman, The Motley Fool - Motley Fool - Mon Jan 13, 3:34PM CST
Lexicon Pharmaceuticals is narrowing its business focus in an effort that will lead to a substantial reduction in head count, and its CEO will also be departing. The company announced that it will concentrate its resources on late-stage drug...
Global Mice Model Market Analysis, 2018: Type, Technology, Disease, Service & Care Products Breakdown
M2 - Fri Jan 10, 8:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dgjm94/mice_model_market) has announced the addition of the "Global Mice Model Market Analysis, 2018" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The biggest factor that is likely to drive the growth of this market is the ongoing innovations in the development of mice models. In addition, another factor that is likely to drive the growth of the market is the continuous research that is undertaken to develop treatments for fatal diseases such as cancer and HIV/AIDS. Furthermore, research institutes and government bodies have extended their help in the form of investments, funds, and grants, which have stimulated research activities to develop mice models. In addition, the demand for personalized medicines is expected to boost the use of humanized mice models. A number of factors such as advancements in the biotechnology and biopharmaceutical industries as well as the increase in the number of R&D activities in pharmaceutical industries are propelling the growth of the mice model market. However, stringent regulations and laws for ethical use of animals in research are hindering the growth of this market. In addition, the market is facing a threat from advances in zebrafish models and rat models, which are leading to their increased use in research activities. North America is the largest market for mice models, followed by Europe and Asia. Furthermore, the Asian and North American markets for mice models are expected to witness a healthy growth over the next five years. Scope of the Report Type - Inbred Mice - Outbred Mice - Conditioned/Surgically Modified Mice - Hybrid/Congenic Mice - Knockout Mice - Spontaneous Mutant Mice Technology - Microinjection - Embryonic Stem Cell Injection - Virus/Vector Mediated Gene Transfer - Nuclear transfer Technology - Genetically Modified Sperm - Others Disease - Oncology - Immunology & Inflammation - Central Nervous System - Cardiovascular - Diabetes - Metabolism & Regulation - Others Service - Breeding - Cryopreservation - Quarantine - Rederivation - Genetic Testing - Model In-licensing - Other Services (Surgical and Line Rescue) Mice Care Products - Bedding - Feed - Cages - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/dg...del_market
Lexicon To Present At The J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 08, 5:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the J. P. Morgan Healthcare Conference on Wednesday, January 15, at 9:30 AM PST in San Francisco. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.
Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)
Brian Orelli, The Motley Fool - Motley Fool - Tue Jan 07, 5:30PM CST
One failed trial followed by a positive one equals an 11% increase in stock price. Technically Neurocrine Biosciences was up 90% today, but it dropped so much after the first trial, the biotech is only sitting on a relatively modest gain from...
The Billion-Dollar Biotech Club: Speculation Trumped Risk
at The Street - Mon Dec 30, 8:19AM CST
The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
UBM plc Begins Trading on OTCQX®
PR Newswire - Wed Dec 18, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that UBM plc (OTCQX: UBMPY; LSE: UBM), a global business-to-business events-led marketing services and communications business, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX®, the best marketplace with qualified companies.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 17, 4:05PM CST
Just as we examine companies each week that may be rising past their fair value , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with companies wallowing at 52-week lows, I...
A Fool’s Look Back at Lexicon, Peregrine, and Jazz
George Budwell, The Motley Fool - Motley Fool - Fri Dec 13, 10:02AM CST
The biotech industry has seen a growing number of specialty companies pop up in the last decade, aiming to develop novel platforms that they can then apply across a number of serious diseases that lack effective treatments. But since so many new...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 07, 7:45AM CST
The past couple of weeks in college football have demonstrated how quickly big mistakes can turn around a game. While the college football season is winding down, we can see the same principle practically every week in the world of health-care...
Setback for Lexicon Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 2:35PM CST
Shares of Lexicon Pharmaceuticals, Inc. (LXRX) were down 6.5% in the last two days after the company reported disappointing results from a phase II study.
Investors look to Lighten Up on Shares of Lexicon Pharmaceuticals, Shares Down 5.1% (LXRX)
Comtex SmarTrend(R) - Thu Dec 05, 12:47PM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 5.1% to $2.06 on 1.5x average daily volume. Lexicon Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 800,000 shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.2%) and underperformed the S&P 500 (-5.1% to the S&P's -0.3%) during today's trading.
